CD79A and Thromboembolism: Further studies in large cohorts of SLE patients are needed to evaluate the association between IgA anti-dsDNA and other clinical manifestations such as skin, central nervous system or serosa involvement, vasculitis, thromboembolism and hematological manifestations.